Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | RBP4 | P02753 | 11/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27297524 | 0.83 | GAA (1.00) | GAAMAPK1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL7817547 | 0.80 | SMN1; SMN2 (0.62) | GAAMAPK1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL766086 | 0.79 | L3MBTL1 (0.64) | RBP4 | |
| SCHEMBL630593 | 0.79 | RBP4 (0.61) | GAAMAPK1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL766323 | 0.77 | RBP4 (0.87) | SMN1; SMN2ALDH1A1TSHRRBP4 | |
| SCHEMBL30996942 | 0.76 | RBP4 (0.61) | MAPK1SMN1; SMN2TSHRRBP4USP2 | |
| SCHEMBL631179 | 0.76 | RBP4 (0.61) | MAPK1SMN1; SMN2TSHRRBP4USP2 | |
| SCHEMBL14627980 | 0.76 | TSHR (0.71) | GAAMAPK1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL632510 | 0.75 | RBP4 (0.57) | MAPK1SMN1; SMN2RBP4USP2 | |
| SCHEMBL31520495 | 0.75 | TSHR (0.74) | GAAMAPK1SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| EP-2419413-B1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853215-B2 | Derivatives of N-acyl-N′-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-07 | — | — | US | disclosed |
| CN-102459209-A | Derivatives of N-acyl-N' -phenylpiperazines for the prevention or treatment of diabetes (etc.) | TAKEDA PHARMACEUTICAL | 2012-05-16 | — | — | CN | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| WO-2010119992-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | GAA 3615/4885MAPK1 4422/4885SMN1; SMN2 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.